Nektar Therapeutics Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Nektar Therapeutics (NKTR) reported its Q3 2025 financial results, revealing a revenue drop to $11.8 million from $24.1 million in Q3 2024, mainly due to the sale of its Huntsville manufacturing facility. The net loss improved slightly to $35.5 million from $37.1 million year-over-year. Operating costs decreased to $43.5 million, attributed to reduced R&D expenses. The company raised capital through stock offerings and received FDA Fast Track designation for its lead product, rezpegaldesleukin, targeting severe alopecia areata. Nektar aims to advance its pipeline and sustain operations into Q2 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments